Congrats to my superstar co-resident @jbierer for winning both the Dr. Paul Cartier Award & the Richard Rowe Competition for his incredible research @SCC_CCS#CCC23! Can't believe he has time for this in between all the life advice I can always depend on him for 😉🥳
@cscs_sccc
In this randomized clinical trial, among infants undergoing heart surgery, delivery of nitric oxide into the cardiopulmonary bypass did not increase ventilator-free survival at 28 days. https://t.co/VJzBLPOP6U
This weekend we celebrated the career of Dr. Chris Feindel and the legacy he leaves behind as he transitions into retirement. Special thanks to @drbarryrubin@OuzounianMD Dr. Rao & Dr. David for sharing their fondest memories & experiences working alongside one of the very best.
Congrats to the @MottChildren cath lab for enrolling their first patient in the COMPASS trial comparing stent vs. shunt for pulmonary blood flow. https://t.co/7NartbQM3M S.O. to Study Co-Chairs and @MottDocs@JennaRomanoMD, @jeffzampi & @skpasquali for their leadership.
Excellent second day at the World Society for Pediatric and Congenital Heart Surgery annual meeting focusing on Tetralogy of Fallot in the beautiful city of Marrakech, Morocco. #wspchs
Achieving the foundational goals of coronary bypass surgery, using innovative revascularization techniques in select patients and strictly adhering to long-term medical therapy optimizes outcomes for patients with coronary artery disease. #sts#coronaryconference
In this trial, patients with three-vessel coronary artery disease, PCI guided by assessment of fractional flow reserve was not noninferior to CABG with respect to the composite end point of death, myocardial infarction, stroke, or repeat revascularization. https://t.co/uYZGZWub0T
In a randomized trial involving patients undergoing mitral-valve surgery for degenerative mitral regurgitation, the addition of tricuspid repair resulted in a lower risk of worsening regurgitation or death. #AHA21 https://t.co/zBNNzSiby8
In a randomized trial, 4,811 patients with atrial fibrillation were assigned to undergo or not undergo left atrial appendage occlusion during cardiac surgery. At 3.8 years, the risk of ischemic stroke or systemic embolism was significantly lower with occlusion. #ACC21
Intermediate-risk patients with aortic stenosis were randomized to transcatheter or surgical aortic-valve replacement (AVR). At five years, there was no significant difference between groups in the rate of death or disabling stroke. https://t.co/mNRr419aZa
#VisualAbstract: A randomized, multicenter trial that compared endovascular repair with open repair of abdominal aortic aneurysm showed no significant difference between these approaches in overall survival after 8 years. Read the full text abstract: https://t.co/AcXsGTe5xW
In the Evolut Low Risk trial, 1468 patients with severe aortic stenosis who were at low risk for death with surgery were assigned to either TAVR with a self-expanding valve or surgical aortic-valve replacement. Read the full abstract: https://t.co/F1Bp7a2qR5
In the PARTNER 3 trial, 1000 patients w/ severe aortic stenosis who were at low risk for death with surgery were assigned to undergo transcatheter aortic-valve replacement with a balloon-expandable valve or surgical aortic-valve replacement. Full results: https://t.co/LNVJq3GqWS